Not The Last Gasp For RespironicsBy
Shares of Respironics (RESP) have been on the skids since it announced in November it was acquiring Healthdyne. Often shares of acquirors drop, but sometimes they rise--or fall only modestly. Respironics fell from 30 to 20 by Jan. 13. A buying opportunity? Elliott Schlang, managing director at the Cleveland investment firm Lynch, Jones & Ryan, thinks so.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.